RFA
ALXN

Reilly Financial Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Reilly Financial Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-8
Closed -$1K – 1041
2018
Q1 		$1K Sell
8
-87
-92% -$10.4K ﹤0.01% 950
2017
Q4 		$11K Sell
95
-20
-17% -$2.44K ﹤0.01% 640
2017
Q3 		$16K Buy
115
+28
+32% +$3.8K ﹤0.01% 551
2017
Q2 		$11K Hold
87
– – ﹤0.01% 635
2017
Q1 		$11K Buy
+87
New +$11.2K ﹤0.01% 601
2015
Q4 		– Sell
-15
Closed -$2K – 1430
2015
Q3 		$2K Buy
+15
New +$2.74K ﹤0.01% 1150
2013
Q3 		– Sell
-25
Closed -$2K – 809
2013
Q2 		$2K Buy
+25
New +$2.41K ﹤0.01% 771

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Reilly Financial Advisors's ALXN Position: Q2 2018 in Review

Reilly Financial Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 8 shares — an estimated $1K sold.

Reilly Financial Advisors first reported a position in ALXN in Q2 2013 and held it in 7 quarters. The position peaked at $16K in Q3 2017. 601 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • Reilly Financial Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Reilly Financial Advisors sold 8 Alexion Pharmaceuticals shares in Q2 2018, an estimated $1K.
  • Reilly Financial Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 7 quarters.
  • Reilly Financial Advisors's Alexion Pharmaceuticals position peaked at $16K in Q3 2017.
  • 601 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Reilly Financial Advisors's 13F filing for Q2 2018, filed 18 Jul 2018.